490 related articles for article (PubMed ID: 16980322)
21. Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis.
Ruffatti A; Sinico RA; Radice A; Ossi E; Cozzi F; Tonello M; Grypiotis P; Todesco S
J Rheumatol; 2002 May; 29(5):918-23. PubMed ID: 12022350
[TBL] [Abstract][Full Text] [Related]
22. Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis.
Teixeira L; Mahr A; Jaureguy F; Noël LH; Nunes H; Lefort A; Barry S; Deny P; Guillevin L
Rheumatology (Oxford); 2005 Feb; 44(2):247-50. PubMed ID: 15546964
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of anti-neutrophil cytoplasmic antibody and pathogenetic role of adhesion molecules for Wegener's granulomatosis].
Takizawa M
Hokkaido Igaku Zasshi; 1996 Jul; 71(4):517-29. PubMed ID: 8809575
[TBL] [Abstract][Full Text] [Related]
24. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.
Schirmer JH; Wright MN; Herrmann K; Laudien M; Nölle B; Reinhold-Keller E; Bremer JP; Moosig F; Holle JU
Arthritis Rheumatol; 2016 Dec; 68(12):2953-2963. PubMed ID: 27333332
[TBL] [Abstract][Full Text] [Related]
25. ANCA in haemodialysis patients.
Weidemann S; Andrassy K; Ritz E
Nephrol Dial Transplant; 1993; 8(9):839-45. PubMed ID: 8255517
[TBL] [Abstract][Full Text] [Related]
26. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.
Miloslavsky EM; Lu N; Unizony S; Choi HK; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Fervenza F; Monach PA; Specks U; Stone JH
Arthritis Rheumatol; 2016 Dec; 68(12):2945-2952. PubMed ID: 27428559
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.
Hagen EC; Daha MR; Hermans J; Andrassy K; Csernok E; Gaskin G; Lesavre P; Lüdemann J; Rasmussen N; Sinico RA; Wiik A; van der Woude FJ
Kidney Int; 1998 Mar; 53(3):743-53. PubMed ID: 9507222
[TBL] [Abstract][Full Text] [Related]
28. Antineutrophil cytoplasmic antibody measurement: advantages and disadvantages of a capture PR3 ELISA and a direct PR3 ELISA.
O'Donnell JL; Hayman MW; Spellerberg MB; McLellan AD; Brooksbank K; Chapman PT; Stamp LK
Pathology; 2007 Apr; 39(2):258-63. PubMed ID: 17454758
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous manifestations of Wegener's granulomatosis: a clinicopathologic study of 17 patients and correlation to antineutrophil cytoplasmic antibody status.
Comfere NI; Macaron NC; Gibson LE
J Cutan Pathol; 2007 Oct; 34(10):739-47. PubMed ID: 17880578
[TBL] [Abstract][Full Text] [Related]
30. [Wegener granulomatosis and microscopic polyangiitis. Diagnostic and clinical results in 54 patients with long-term follow-up].
Bolley R; Mistry-Burchardi N; Samtleben W
Dtsch Med Wochenschr; 2000 Dec; 125(50):1519-25. PubMed ID: 11190761
[TBL] [Abstract][Full Text] [Related]
31. Analytical and diagnostic accuracy of the EliA automated enzyme fluoroimmunoassay for antineutrophil cytoplasmic autoantibody detection.
Villalta D; Tonutti E; Tampoia M; Bizzaro N; Papisch W; Tozzoli R; Stella S
Clin Chem Lab Med; 2004; 42(10):1161-7. PubMed ID: 15552276
[TBL] [Abstract][Full Text] [Related]
32. [Antineutrophil cytoplasmic antibody(ANCA)].
Yoshida M
Rinsho Byori; 2003 Jul; 51(7):644-8. PubMed ID: 12924248
[TBL] [Abstract][Full Text] [Related]
33. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission.
Abdulahad WH; Stegeman CA; Limburg PC; Kallenberg CG
Arthritis Rheum; 2008 Jul; 58(7):2196-205. PubMed ID: 18576340
[TBL] [Abstract][Full Text] [Related]
34. Antineutrophil cytoplasmic autoantibody testing in vasculitides.
Gross WL
Rheum Dis Clin North Am; 1995 Nov; 21(4):987-1011. PubMed ID: 8592745
[TBL] [Abstract][Full Text] [Related]
35. Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis.
Sinico RA; Radice A; Corace C; DI Toma L; Sabadini E
Ann N Y Acad Sci; 2005 Jun; 1050():185-92. PubMed ID: 16014533
[TBL] [Abstract][Full Text] [Related]
36. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions.
Russell KA; Wiegert E; Schroeder DR; Homburger HA; Specks U
Clin Immunol; 2002 May; 103(2):196-203. PubMed ID: 12027425
[TBL] [Abstract][Full Text] [Related]
37. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
Lionaki S; Blyth ER; Hogan SL; Hu Y; Senior BA; Jennette CE; Nachman PH; Jennette JC; Falk RJ
Arthritis Rheum; 2012 Oct; 64(10):3452-62. PubMed ID: 23023777
[TBL] [Abstract][Full Text] [Related]
38. Antineutrophil cytoplasmic antibodies (ANCA).
Radice A; Sinico RA
Autoimmunity; 2005 Feb; 38(1):93-103. PubMed ID: 15804710
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA.
Schönermarck U; Lamprecht P; Csernok E; Gross WL
Rheumatology (Oxford); 2001 Feb; 40(2):178-84. PubMed ID: 11257154
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis.
Zhang AH; Chen M; Gao Y; Zhao MH; Wang HY
Clin Immunol; 2007 Feb; 122(2):187-93. PubMed ID: 17070108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
